Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AGER | Q15109 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21608272 | 0.85 | HTR2A (0.39) | HTR2CHTR2AALDH1A1MAPTAGER | |
| SCHEMBL21608469 | 0.79 | HTR2C (0.36) | HTR2CHTR2ASLC2A1HTR2BRXFP1 | |
| SCHEMBL21608323 | 0.79 | HTR2C (0.39) | HTR2CHTR2ASLC2A1HTR2BRXFP1 | |
| SCHEMBL21608523 | 0.79 | RXFP1 (0.36) | HTR2CHTR2AKDM4EMAPTRXFP1 | |
| SCHEMBL21608521 | 0.79 | GRIN2B (0.38) | HTR2CHTR2AKDM4EALDH1A1GRIN2B | |
| SCHEMBL21608360 | 0.78 | GRIN2B (0.44) | ACACBGRIN2B | |
| SCHEMBL21608318 | 0.76 | RXFP1 (0.34) | HTR2CKDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL21608526 | 0.76 | PTGDR2 (0.35) | KDM4EACACBGRIN2BRXFP1 | |
| SCHEMBL21608387 | 0.75 | HTR2A (0.35) | HTR2CHTR2AKDM4EMAPTRXFP1 | |
| SCHEMBL23885112 | 0.74 | KMT2A (0.45) | KDM4EALDH1A1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | HTR2C 3906/4885HTR2A 2986/4885KDM4E 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.